论文部分内容阅读
Background: Strontium (Sr) ralenate is a new agent for postmenopausal osteoporosis.In vitro study suggested that Sr had the potential to increase osteoblastic/progenitor cells differentiation and decrease osteoclast differentiation and resorption activity1, 2.